Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
about
Clinical management of grade III oligodendrogliomaOligodendroglioma: pathology, molecular mechanisms and markersEpidemiologic and molecular prognostic review of glioblastomaParadoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation StatusMachine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlatesNovel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images.Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.Synchronous multicentric glioblastoma with PNET and O subtypes: Possible pathogenesisImpact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.Using the molecular classification of glioblastoma to inform personalized treatment.Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.Reduced PTEN expression and overexpression of miR-17-5p, -19a-3p, -19b-3p, -21-5p, -130b-3p, -221-3p and -222-3p by glioblastoma stem-like cells following irradiation.Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro.Down-regulation of the long noncoding RNA-HOX transcript antisense intergenic RNA inhibits the occurrence and progression of glioma.The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter.Dynamic study of methionine positron emission tomography in patients with glioblastoma with oligodendroglial components.Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expression.Expression of p53 & epidermal growth factor receptor in glioblastoma.
P2860
Q26801254-21C43EC4-1354-4BEA-87D6-B62F2967F84BQ27002448-9EAE00F1-0457-49CC-B766-2017E814D6E8Q28395302-7C801E33-B852-478F-A201-213F5B8CFFB5Q30984368-9C16236D-81CC-4EA7-AE4F-E1236CBA1122Q35028828-2FD068D5-688C-48ED-B38A-436426C91BA3Q35044026-F9F8721A-D116-48AD-80E9-654E4081897DQ35544567-50F1B4A8-745B-404C-BD16-7F1B9EE2A788Q36457608-D7329501-CB7B-4E6F-8804-BB5BBAE828EAQ37715158-1EF91140-A241-45B6-B0DB-1365BD62EB14Q37746324-69F21CFB-CE4E-4359-8DFA-D7C2781DF487Q38151582-D310AB8E-BB63-458A-AD73-42E7C99833CBQ38601004-0F4D5ABC-91E3-4C5A-A9DF-4335DF3158E1Q38815443-9A4C89CD-8A7D-4841-BCAB-62C18B7F19CDQ38957338-672E4A44-B08B-453C-B6AF-7C4DC70E77FDQ39029492-148C82C2-6C1D-4E15-84B7-03E091CB615BQ39091307-DA09691B-1164-452D-99E5-4A9789085F7CQ47773621-0CB156CA-00FE-41FD-B5C1-744F8ADBC752Q47844364-FD38FF4B-4DD8-4753-8F49-663182D21240Q48133028-65E3B9E6-F61B-49A8-A7B9-0E027309D32BQ48234395-6E442A9A-3BA2-4E9E-8585-0E0E3A7E9E7DQ48261392-EFC4BBED-E442-4AD3-9773-2304991BC397Q48453105-DB9E6D48-0F80-4E79-993F-D93D2153FADAQ48797026-29E0E2A6-06AA-46D2-A92E-E1E748F04162Q55005059-D9816B96-6DAD-4458-A375-CCF01FA02400Q55317834-A3C754E2-79D5-400D-84AD-EBE52BBF4F69
P2860
Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Glioblastoma with oligodendrog ...... and clinical characteristics.
@en
type
label
Glioblastoma with oligodendrog ...... and clinical characteristics.
@en
prefLabel
Glioblastoma with oligodendrog ...... and clinical characteristics.
@en
P2093
P2860
P356
P1433
P1476
Glioblastoma with oligodendrog ...... and clinical characteristics.
@en
P2093
Candace Chisolm
Christina L Appin
Chunhai Hao
Costas Hadjipanayis
Cristina Vincentelli
Daniel J Brat
Dianne Alexis
Jeffrey J Olson
Jingjing Gao
Matthew J Schniederjan
P2860
P304
P356
10.1111/BPA.12018
P577
2013-01-30T00:00:00Z